This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Griffith, K Articles by Pagani, F. Search for Related Content PubMed PubMed Citation Articles by Griffith, K Articles by Pagani, F. Social Bookmarking                         What's this?

First American experience with the Terumo DuraHeart^TM left ventricular assist system

University of Michigan Hospitals, Michigan, USAkegriff{at}med.umich.edu

E Jenkins

University of Michigan Hospitals, Michigan, USA

FD Pagani

Heart Transplant Program and Center for Circulatory Support, University of Michigan Hospitals, Michigan, USA

Since the first implantation of a left ventricular assist system (LVAS) 45 years ago, LVAS therapy has emerged as a viable option for the treatment of advanced heart failure. The current generation of LVASs in clinical evaluation has design features enabling longer and more reliable support durations. We describe the operating characteristics of the DuraHeart^TM LVAS (Terumo Heart, Inc., Ann Arbor, MI). The DuraHeart^TM LVAS is a magnetically-levitated centrifugal pump that began a FDA-approved clinical trial for evaluation of bridge to transplant indication in July of 2008. Magnetic levitation of the spinning-pump impeller is hypothesized to improve long-term mechanical reliability and biological compatibility of the pump. Other design features make the DuraHeart^TM LVAS particularly suited for implantation without cardiopulmonary bypass (CPB). A description of the implant procedure for the first six American implants of the DuraHeart^TM LVAS both on-CPB and off-CPB, including CPB techniques employed, are discussed. While it is still very early in the DuraHeart^TM LVAS experience, the initial outcomes of the first six patient implants would suggest that the device is a safe and effective LVAS.

Perfusion, Vol. 24, No. 2, 83-89 (2009)
DOI: 10.1177/0267659109106826


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?